ITHACA, N.Y. — A drug already sitting on pharmacy shelves may offer a new way to attack a rare liver cancer that medicine has largely failed to stop. Fibrolamellar carcinoma makes up about 2% of all liver cancers. It hits children and young adults.
There is no cure. By the time doctors find it, the disease has usually spread.
Standard immunotherapy has shown little effect. Now researchers think they know why. A study published in the journal Gastroenterology mapped out what happens inside the tumor.
Scientists from Cornell University and the University of Washington found that the cancer builds a kind of cellular trap. It keeps the body’s own immune cells away from the tumor itself.
The process has a name: T cell exclusion. Immune T cells are the soldiers the body sends to fight disease. In fibrolamellar carcinoma, those cells get pulled into nearby fibrous tissue instead of reaching the cancer.
They end up stuck there, useless. This likely explains why immune checkpoint inhibitors — a common immunotherapy that works by taking the brakes off T cells — have failed against this cancer. The T cells never reach the fight in the first place.
The team used a technology called single-nucleus transcriptomics to figure out how this happens. It lets researchers look at gene activity inside individual cells.
That analysis showed that altered liver stellate cells produce the fibrous bands that give the cancer its name. Those same cells release signals that lure T cells away from the tumor. Then came the drug test.
The researchers tried AMD3100, a compound already approved by the FDA for other uses. Working with slices of actual tumor tissue taken from patients, they found the drug blocked the signals that were trapping the T cells.
Once the signal stopped, the immune cells moved back into the tumors. The combination mattered. When the team paired AMD3100 with immune checkpoint inhibitors, they saw stronger T cell activity.
Cancer cell death increased significantly compared to immunotherapy alone. The findings suggest a straightforward strategy. Target the T cell exclusion first.
Then let immunotherapy do its job. This is not a cure yet.
The work was done on tumor tissue in a lab, not in living patients. Clinical trials would be needed to see if the approach works in people. But the drug is already approved, which could speed things up.
Fibrolamellar carcinoma is rare. That makes it hard to study and harder to fund.
Big drug companies rarely chase treatments for diseases that affect a few thousand people. A drug already on the market bypasses some of that problem. The study offers one of the clearest explanations yet for why the immune system fails against this cancer.
It also provides a specific mechanism to disrupt. The trap exists. Now there is a way to spring it.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Researchers Identify Why Immunotherapy Fails in Rare Liver Cancer Fibrolamellar Carcinoma”, “description”: “ITHACA, N.Y. — A drug already sitting on pharmacy shelves may offer a new way to attack a rare liver cancer that medicine has largely…”, “datePublished”: “2026-07-05T04:13:33+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Noah King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
